ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)"

  • Abstract Number: 1592 • ACR Convergence 2024

    Overlapping Forms of Eosinophilic Granulomatosis with Polyangiitis and Granulomatosis with Polyangiitis: Presentation, Management and Outcomes

    Federica Pallotti1, Camille Mettler2, Roberto Padoan3, Francesca Regola4, Franco Franceschini5, Sergey Moiseev6, Pavel Novikov7, Mario Andrea Piga8, Gianluca Moroncini9, Silke Brix10, Abdul Hadi Kafagi11, Samuel Deshayes12, Achille Aouba12, Julien Campagne13, Paolo Delvino14, Jan Willem Cohen Tervaert15, Luisa Brussino16, Martin Michaud17, Nils Venhoff18, Federico Alberici19, Claudia Iannone20, Sophie Rosenstingl21, Marin Moutel22, Jean-Marc Galempoix23, Vincent Cottin24, Clara Jaccard25, Diane Riehl26, Paul Legendre27, Anne-Claire Billet28, Paola Parronchi29, Luca Quartuccio30, Vítor Silvestre Teixeira31, Allyson Egan32, David Jayne32, Enrico Tombetti33, Marco Caminati34, Christian Pagnoux35, Alexis Régent36, Marc Ruivard37, Loïc Guillevin38, Xavier Puéchal36 and Benjamin Terrier39, and the French Vasculities Study Group and European EGPA Study Group, 1Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, 2Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, 3Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, 4Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, 5Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 6Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia, 7Sechenov First Moscow State Medical University, Moscow, Russia, 8Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, Ancona, Italy, 9Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Marche University Hospital, Ancona, Italy, 10Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom, 11Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom, 12Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, 13Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, 14University of Milano-Bicocca, Milan, Milan, Italy, 15University of Alberta, Edmonton, Canada, 16SSDDU Immunologia Clinica ed Allergologia, AO Mauriziano, Turin, Italy, 17Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, 18Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, 19Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, 20Department of Rheumatology, University of Milan, and Rheumatology Department, ASST Pini-CTO, Milan, Italy, 21Service Médecine Interne, Centre hospitalier intercommunal Compiègne Noyon, Compiègne Noyon, France, 22Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, Reims University Hospital, Reims, France, 23J.M. Galempoix, MD, Department of Internal Medicine, Nord Ardennes Hospital, Charleville-Mézières, France, 24Hôpital Louis Pradel, Centre de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France, Lyon, France, 25Gaston Bourret Hospital, Nouméa, New Caledonia, 26Centre hospitalier intercommunal Toulon- La Seyne Sur Mer, Toulon, France, 27Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, 28Department of Internal Medicine, Édouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France, 29University of Florence, Florence, Florence, Italy, 30Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, 31Department of Rheumatology, Faro Hospital, Algarve, Portugal, 32University of Cambridge, Cambridge, United Kingdom, 33Internal Medicine and Rheumatology, Department of Biomedical and Clinical Sciences, Sacco and Fatebenefratelli Hospitals, Milan, Italy, Milan, Italy, 34Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, 35Mount Sinai Hospital, Toronto, ON, Canada, 36National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 37Internal Medicine Department, Estaing University Hospital, CHU Clermont-Ferrand, Clermonnt-Ferrand, Italy, 38National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 39Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: ANCA-associated vasculitis (AAV) include granulomatosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (EGPA). Although these entities are often easily distinguished in…
  • Abstract Number: 2491 • ACR Convergence 2024

    Treatment Outcomes of Eosinophilic Granulomatosis with Polyangiitis (EGPA):A Retrospective Analysis of US Health Insurance Claims Data

    Paul Dolin1, Anat Shavit1, Karina A. Keogh2, Jennifer Rowell3, Chris Edmonds4, Danuta Kielar5, Juliana Meyers6, Elizabeth Esterberg6, Tram Nham6 and Stephanie Y. Chen7, 1BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, 6RTI Health Solutions, Research Triangle Park, NC, 7BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis disorder characterized by asthma, eosinophilia and the presence of eosinophilic inflammation. Patients with EGPA are…
  • Abstract Number: 1593 • ACR Convergence 2024

    Efficacy of Increasing the Dose of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis

    Federica Pallotti1, Philippe Bonniaud2, Perrine SMETS3, stephanie Habib4, Amandine Perier5, Alban Deroux6, Julie Mankikian7, Antoine Neel8, Clémentine Rousselin9, Raphaele Seror10, Camille Taille11, Etienne Crickx12, Candice La Croix13, Philippe Blanche14, Loïc Guillevin15, Xavier Puéchal16 and Benjamin Terrier17, and French Vasculitis Study Group, 1Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, 2Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, 3Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, 4Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, 5CH de Niort, Niort, France, 6Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, 7CHRU Tours, Service de Pneumologie et d'Explorations Fonctionnelles Respiratoires, Tours, France, 8Department of Internal Medicine, CHU Nantes, Nantes, France, 9Service de médecine interne et néphrologie, centre hospitalier de Valenciennes, Valenciennes, France, 10Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 11Bichat Hospital, Paris, France, 12Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, APHP, Paris, France, 13Department of Otolaryngology, Hôpital Cochin, APHP, Paris, France, 14Department of Internal Medicine, National Referrence Center for Systemic and Autoimmune Diseases, Hôpital Cochin, APHP, Paris, France, 15National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 16National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 17Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) patients frequently develop glucocorticoid (GC)-dependent asthma and/or ENT manifestations, leading to long-term GC requirement and side effects. Mepolizumab, an…
  • Abstract Number: 2691 • ACR Convergence 2024

    Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis

    Roberto Ríos-Garcés1, Núria Farran1, Salvador Naranjo-Suarez2, Roser Alba-Rovira1, Sergio Prieto-González3, Itziar Tavera-Bahillo1, Roser Solans-Laqué4, Ebymar Arismendi5, Marc Corbera-Bellalta1, Javi Marco-Hernández1, Farah Kamberovic1, Nina Visocnik1, Maria Cid6 and Georgina Espígol-Frigolé1, 1Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 2Angiogenesis in Liver Disease Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 3Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, bar, Spain, 4Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, 5Pneumology Department, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain, 6Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain

    Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…
  • Abstract Number: 1594 • ACR Convergence 2024

    Response to Mepolizumab Therapy in a Single-center Cohort of Eosinophilic Granulomatosis with Polyangiitis Patients: Characterization of Cytokine/Chemokine Pattern and Phenotypic Stratification

    Michele Moretti1, Francesco Ferro2, Irene Martelli3, Francesca Pistone3, Giulia Greco3, Federica Di Cianni4, Nazzareno Italiano5, ROSARIA TALARICO4, Veronica Seccia6, Chiara Baldini7, Ilaria Puxeddu3 and Marta Mosca7, 1University of Pisa, Pisa, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 4University of Pisa, Pisa, Italy, 5University of Pisa, Rovigo, Italy, 6Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, 7University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy

    Background/Purpose: The introduction of Mepolizumab treatment has revolutionized the therapy of EGPA and has promoted the search for biomarkers predictive of response to treatment. However,…
  • Abstract Number: 1596 • ACR Convergence 2024

    Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis

    Bernhard Hellmich1, Peter Merkel2, David Jayne3, Benjamin Terrier4, Florence Roufosse5, Parameswaran Nair6, Nader Khalidi6, David J. Jackson7, Shunsuke Furuta8, Lena Börjesson Sjö9, Sofia Necander9, Anat Shavit10, Claire Walton11 and Michael Wechsler12, 1Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 2University of Pennsylvania, Philadelphia, PA, 3University of Cambridge, Cambridge, United Kingdom, 4Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 5Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, 6McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, 7Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Trust; School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom, 8Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, 9Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 10BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 11Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 12National Jewish Health, Denver, CO

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis, with individual manifestations widely ranging…
  • Abstract Number: 1599 • ACR Convergence 2024

    Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis with Poor-Prognosis Factors: A Target Trial Emulation Study

    Boris Sorin1, Matthias Papo1, Renato Alberto Sinico2, Vítor Silvestre Teixeira3, Nils Venhoff4, Maria-Letizia Urban5, Michele Iudici6, Juliane Mahrhold7, Francesco Locatelli8, Giulia Cassone9, Franco Schiavon10, Benjamin Seeliger11, Thomas Neumann12, Claudia Feder13, Claus Kroegel14, Matthieu Groh15, Chiara Marvisi16, Maxime Samson17, Thomas Barba18, David Jayne19, Arianna Troilo20, Jens Thiel20, Bernhard Hellmich21, Sara Monti22, Carlomaurizio Montecucco23, Carlo Salvarani24, Jean-Emmanuel Kahn25, Bernard Bonnotte26, Cécile-Audrey Durel27, Xavier Puéchal28, Luc Mouthon29, Loïc Guillevin30, Giacomo Emmi31, Augusto Vaglio32, Raphael Porcher33 and Benjamin Terrier34, and the French Vasculitis Study Group (FVSG) and the European EGPA Study Group (EESG), 1Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris, Paris, France, 2Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Milan, Italy, 3Department of Rheumatology, Faro Hospital, Algarve, Portugal, 4Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, 5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 6Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris and Division of rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland, Paris, France, 7Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabtologyy and Immunology, ERN-RITA Reference Center, Vasculitis-Center Tübingen-Kirchheim, Medius Kliniken Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, 8Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, 9Clinical and Experimental Medicine PhD Program, Azienda USL-IRCCS di Reggio Emilia and Universita di Modena and Reggio Emilia, Modena, Italy, 10Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, 11Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 12Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany and Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St Gallen, Switzerland, Jena, Germany, 13Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany, 14Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, 15Foch, Suresnes, France, 16Rheumatology Unit Universita di Modena and Reggio Emilia, Modena, Italy, 17Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, 18Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, 19University of Cambridge, Cambridge, United Kingdom, 20Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany, 21Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 22IRCCS Istituto Auxologico Italiano, Milan, Italy, 23IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 24Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, 25Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France, Boulogne Billancourt, France, 26Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France, 27Edouard Herriot University Hospital, Lyon, France, 28National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 29Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l'Est et de l'Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 30National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 31Department of Medical, Surgery and Health Sciences, University of Trieste, and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, 32Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, 33Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, 34Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel necrotizing vasculitis characterized by asthma, blood and tissue eosinophilia and vasculitis affecting multiple organs. According to…
  • Abstract Number: 1600 • ACR Convergence 2024

    Glucocorticoids versus Glucocorticoids Plus Cyclophosphamide in Eosinophilic Granulomatosis with Polyangiitis Without Poor-Prognosis Factors: A Target Trial Emulation Study

    Boris Sorin1, Matthias Papo1, Renato Alberto Sinico2, Vítor Silvestre Teixeira3, Nils Venhoff4, Maria-Letizia Urban5, Michele Iudici6, Juliane Mahrhold7, Francesco Locatelli8, Giulia Cassone9, Franco Schiavon10, Benjamin Seeliger11, Thomas Neumann12, Claudia Feder13, Claus Kroegel14, Matthieu Groh15, Chiara Marvisi16, Maxime Samson17, Thomas Barba18, David Jayne19, Arianna Troilo20, Jens Thiel20, Bernhard Hellmich21, Sara Monti22, Carlomaurizio Montecucco23, Carlo Salvarani24, Jean-Emmanuel Kahn25, Bernard Bonnotte26, Cécile-Audrey Durel27, Xavier Puéchal28, Luc Mouthon29, Loïc Guillevin30, Giacomo Emmi31, Augusto Vaglio32, Raphael Porcher33 and Benjamin Terrier34, and the French Vasculitis Study Group (FVSG) and the European EGPA Study Group (EESG), 1Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris, Paris, France, 2Nephrology and Dialysis Unit, IRCCS Humanitas Research Hospital, Milan, Italy, 3Department of Rheumatology, Faro Hospital, Algarve, Portugal, 4Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, 5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 6Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune and Autoinflammatory Diseases of Ile de France, East and West, Paris Cité University, Assistance Publique – Hôpitaux de Paris and Division of rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland, Paris, France, 7Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabtologyy and Immunology, ERN-RITA Reference Center, Vasculitis-Center Tübingen-Kirchheim, Medius Kliniken Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, 8Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, 9Clinical and Experimental Medicine PhD Program, Azienda USL-IRCCS di Reggio Emilia and Universita di Modena and Reggio Emilia, Modena, Italy, 10Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, 11Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 12Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany and Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St Gallen, Switzerland, Jena, Germany, 13Department of Rheumatology, Clinic of Internal Medicine III, Jena University Hospital, Jena, Germany, 14Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, 15Foch, Suresnes, France, 16Rheumatology Unit Universita di Modena and Reggio Emilia, Modena, Italy, 17Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, 18Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, 19University of Cambridge, Cambridge, United Kingdom, 20Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany, 21Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, 22IRCCS Istituto Auxologico Italiano, Milan, Italy, 23IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 24Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, 25Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France, Boulogne Billancourt, France, 26Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France, 27Edouard Herriot University Hospital, Lyon, France, 28National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, 29Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l'Est et de l'Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 30National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, 31Department of Medical, Surgery and Health Sciences, University of Trieste, and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste, Italy, 32Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, 33Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, 34Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, blood and tissue eosinophilia and vasculitis affecting multiple organs. According to the…
  • Abstract Number: 1601 • ACR Convergence 2024

    Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023

    Lynn Fussner1, Christian Pagnoux2, David Cuthbertson3, Thomas Corbridge4, Nader Khalidi5, Curry Koening6, Carol Langford7, Carol McAlear8, Paul Monach9, Larry Moreland10, Rennie Rhee8, Philip Seo11, Anat Shavit12, Jared Silver13, Ulrich Specks14, Kenneth Warrington14, Michael Wechsler15 and Peter Merkel8, and for the Vasculitis Clinical Research Consortium, 1The Ohio State University, Columbus, OH, 2Mount Sinai Hospital, Toronto, ON, Canada, 3University of South Florida, Tampa, FL, 4US Value Evidence and Outcomes, GSK, Durham, NC, 5McMaster University, Hamilton, ON, Canada, 6University of Texas Dell Medical School, Austin, TX, 7Cleveland Clinic, Moreland Hills, OH, 8University of Pennsylvania, Philadelphia, PA, 9VA Boston Healthcare System, Boston, MA, 10University of Colorado, Denver, CO, 11Johns Hopkins University, Baltimore, MD, 12BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 13US Medical Affairs - Respiratory, GSK, Durham, 14Mayo Clinic, Rochester, MN, 15National Jewish Health, Denver, CO

    Background/Purpose: The emergence of biologic therapies targeting eosinophils via the IL-5 pathway provided new options for treatment in eosinophilic granulomatosis with polyangiitis (EGPA). There has…
  • Abstract Number: 1604 • ACR Convergence 2024

    Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis

    Peter Merkel1, Peter Baudy2, Donna Carstens2, Benjamin North3, Mahvish Danka3, Stephanie Roy3, Hanna Marshall3 and Geoffrey Chupp4, 1University of Pennsylvania, Philadelphia, PA, 2Respiratory & Immunology US Medical, AstraZeneca, Wilmington, 3IQVIA, Philadelphia, 4School of Medicine, Yale University, New Haven

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis that can present indolently. This can lead to a delay in diagnosis and treatment. This study…
  • Abstract Number: 1605 • ACR Convergence 2024

    Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis

    Peter Merkel1, David Jayne2, Ulrich Specks3, Christian Pagnoux4, Parameswaran Nair5, Nader Khalidi5, Arnaud Bourdin6, Lena Börjesson Sjö7, Sofia Necander7, Anat Shavit8, Claire Walton9 and Michael Wechsler10, 1University of Pennsylvania, Philadelphia, PA, 2University of Cambridge, Cambridge, United Kingdom, 3Mayo Clinic, Rochester, MN, 4Mount Sinai Hospital, Toronto, ON, Canada, 5McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, 6Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France, 7Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 9Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 10National Jewish Health, Denver, CO

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis. In the Phase 3, double-blind,…
  • Abstract Number: 1606 • ACR Convergence 2024

    Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data

    Paul Dolin1, Anat Shavit1, Karina A. Keogh2, Jennifer Rowell3, Chris Edmonds4, James M. Eudicone5, Amanda M. Moore6, Melissa Wilson7, Kinwei A. Chan6, Thomas Peer8 and Stephanie Y. Chen9, 1BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, 3Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, 4Market Access and Pricing, AstraZeneca, Gaithersburg, MD, 5Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 6TriNetX, Cambridge, MA, 7TriNetX, Durham, NC, 8TriNetX, Farmington, NY, 9BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by chronic necrotizing vasculitis. Conventional therapy (oral glucocorticoids [OGC] ± immunosuppressants), mepolizumab, and…
  • Abstract Number: 1607 • ACR Convergence 2024

    Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

    Sebastian Klapa1, Sabrina Arnold2, Antje Müller2, Andreas Koch3, Anja Staehle4, Wataru Kähler3, Harry Heidecke5, Gabriela Riemekasten2 and Peter Lamprecht2, 1University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, 2University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 3Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, 4University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, 5CellTrend GmbH, Luckenwalde, Germany

    Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
  • Abstract Number: 1608 • ACR Convergence 2024

    Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes

    Janelle Castellino1, Matas Orentas2, Joshua Moran3, Joshlean Fair1, Yanyu Zhang4 and Aleksandra Bukiej5, 1Rush University Medical Center, Chicago, IL, 2RUMC, Chicago, IL, 3Rush University Medical Center - IM Residency, Chicago, IL, 4Rush University Medical Center, Chicago, 5Rush University Medical Center, River Forest, IL

    Background/Purpose: Interstitial lung disease (ILD) is a significant manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and…
  • Abstract Number: 1611 • ACR Convergence 2024

    Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study

    Paolo Delvino1, Luca Quartuccio2, Joanna Robson3, Federico Alberici4, Diego Bagnasco5, Alvise Berti6, Marco Caminati7, Marta Camoni8, Maria Cid9, Edoardo Conticini10, Giulia Costanzo11, Claire de Moreuil12, Stefano Del Giacco11, Georgina Espigol-Frigole13, Virginia V Ferretti14, Franco Franceschini15, Luca Iorio16, Anna Kernder17, Catherine Klersy14, Alberto Lo Gullo18, Laura Losappio19, Elena Manna20, Matteo Maule21, Carlomaurizio Montecucco22, Negrini Simone23, Roberto Padoan24, Francesca Regola25, Luisa Ricciardi26, Jan Schroeder19, Benjamin Terrier27, Paola Toniati28, Elena Treppo2, Maria-Letizia Urban29, Augusto Vaglio30, Giacomo Emmi31 and Sara Monti32, and European EGPA Study Group, 1University of Milano-Bicocca, Milan, Milan, Italy, 2Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, 3UWE Bristol, Bristol, United Kingdom, 4Nephrology Unit, University of Brescia, ASST Spedali Civili, University of Brescia, Brescia, Italy, Brescia, Italy, 5Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI), IRCCS Policlinico San Martino, Genoa, Italy, 6University of Trento, Rochester, Italy, 7Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, 8Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy, 9Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain, 10University of Siena, Siena, Siena, Italy, 11Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, 12Service de médecine interne, CHU de Brest, Brest, France, 13Hospital Clinic de Barcelona, Barcelona, Spain, 14Biostatistcs & Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, 15Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 16Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy, 17HHU Dusseldorf, Dusseldorf, Germany, 18Rheumatology Unit, Papardo Hospital, Messina, Italy, 19Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Milan, Italy, 20Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, 21Asthma Center and Allergy Unit, Verona Integrated University Hospital, Verona, Verona, Italy, 22IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 23Department of Internal Medicine (DIMI), University of Genoa, Genoa, Genoa, Italy, 24Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, 25Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, 26Allergy and Immunology Unit, Department of Clinical and Experimental Medicine, G. Martino Teaching Hospital, University of Messina, Messina, Messina, Italy, 27Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, 28Spedali civili, 25123, Italy, 29Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 30Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, 31University of Trieste, Trieste, Italy, 32IRCCS Istituto Auxologico Italiano, Milan, Italy

    Background/Purpose: Mepolizumab (MEPO) proved its efficacy in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in the randomized controlled MIRRA trial. The ANCA-associated vasculitis patient-reported…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology